StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

ISIC C21 · United States · 6 publishers

Pharmaceuticals in United States

116 verified figures for United States, covering 51 indicators from 6 primary sources. Every figure links to the report it came from.

JSON Cite and reuse

116 verified figures Updated 27 Sep 2026 Reviewed 17 Sep 2026 Update cycle: irregular

United States compared

MeasureUnited StatesWorldHighest country
Alzheimer's disease drug trial starts128United States · 1 Jan 2023 to 27 Sep 2026269World · 1 Jan 2023 to 27 Sep 2026United States is highest
Antibody-drug conjugate trial starts428United States · 1 Jan 2023 to 27 Sep 20261,225World · 1 Jan 2023 to 27 Sep 2026638China · 1 Jan 2023 to 27 Sep 2026
Autoimmune cell therapy and T-cell engager trial starts67United States · 1 Jan 2023 to 27 Sep 2026300World · 1 Jan 2023 to 27 Sep 2026185China · 1 Jan 2023 to 27 Sep 2026
Cardiometabolic RNA and next-generation lipid drug trial starts90United States · 1 Jan 2023 to 27 Sep 2026128World · 1 Jan 2023 to 27 Sep 2026United States is highest
GLP-1, incretin multi-agonist and amylin trial starts378United States · 1 Jan 2023 to 27 Sep 2026798World · 1 Jan 2023 to 27 Sep 2026United States is highest
Gene editing trial starts54United States · 1 Jan 2023 to 27 Sep 2026133World · 1 Jan 2023 to 27 Sep 202654China · 1 Jan 2023 to 27 Sep 2026

The short version

Key takeaways

Market size and output 2

  1. Net medicine spending in the United States was 606 billion USD in 2025 (IQVIA). IQVIA ↗
  2. Cardiometabolic RNA and next-generation lipid drug trial starts in the United States were 26 in 2025 (ClinicalTrials.gov). ClinicalTrials.gov ↗ T1 Official

Growth and change 4

  1. COVID-19 vaccines and therapeutics spending decline in the United States was 4 billion USD in 2025 (IQVIA). IQVIA ↗
  2. Net medicine spending increase in the United States was 58 billion USD in 2025 (IQVIA). IQVIA ↗
  3. Medicare patient out-of-pocket medicine cost decline in the United States was 638 million USD in 2025 (IQVIA). IQVIA ↗
  4. Patient out-of-pocket medicine cost increase in the United States was 6 billion USD in 2025 (IQVIA). IQVIA ↗

Prices and costs 1

  1. Patient out-of-pocket medicine costs in the United States were 110 billion USD in 2025 (IQVIA). IQVIA ↗

Other measures 3

  1. Pharmaceutical and medicine manufacturing R&D funded by domestic companies in the United States was 2,104 million USD in 2023 (NCSES). NCSES ↗ T1 Official
  2. Pharmaceutical and medicine manufacturing R&D funded by foreign companies in the United States was 9 billion USD in 2023 (NCSES). NCSES ↗ T1 Official
  3. Pharmaceutical and medicine manufacturing R&D funded by other external sources in the United States was 79 million USD in 2023 (NCSES). NCSES ↗ T1 Official

The complete table

Pharmaceuticals data for United States

Every row links to its own page with the full source, verbatim quote and citation.

116 data points across 51 indicators. Each line shows the latest value; open a line for earlier periods and forecasts.

Download CSV
IndicatorPeriodValueSourceType
Alzheimer's disease drug trial starts+6 more1 Jan 2023 to 27 Sep 2026128ClinicalTrials.govT12026actual→
Antibody-drug conjugate trial starts+6 more1 Jan 2023 to 27 Sep 2026428ClinicalTrials.govT12026actual→
Autoimmune cell therapy and T-cell engager trial starts+6 more1 Jan 2023 to 27 Sep 202667ClinicalTrials.govT12026actual→
Biosimilar biological product approvals202418FDAT12024actual→
Cardiometabolic RNA and next-generation lipid drug trial starts+6 more1 Jan 2023 to 27 Sep 202690ClinicalTrials.govT12026actual→
Cell and gene therapy spending share by geography202362%IQVIA2023actual→
Clinical trial country use share2021–202316%IQVIA2023actual→
COVID-19 vaccines and therapeutics spending decline20254 billion USDIQVIA2025actual→
First-cycle novel drug approvals202437FDAT12024actual→
Five-year cumulative medicine use growth2020–202513%IQVIA2025actual→
Gene editing trial starts+6 more1 Jan 2023 to 27 Sep 202654ClinicalTrials.govT12026actual→
GIP/GLP-1 agonist spending growth contribution202514 billion USDIQVIA2025actual→
GLP-1, incretin multi-agonist and amylin trial starts+6 more1 Jan 2023 to 27 Sep 2026378ClinicalTrials.govT12026actual→
Health sector research and development investment growth rate20247.1%European CommissionT12025actual→
Inflammatory bowel disease drug trial starts+6 more1 Jan 2023 to 27 Sep 2026146ClinicalTrials.govT12026actual→
Interchangeable biosimilar approvals20249FDAT12024actual→
KRAS and RAS inhibitor trial starts+6 more1 Jan 2023 to 27 Sep 2026116ClinicalTrials.govT12026actual→
Life sciences and patient organization deal value1 Jan 2008 to 5 Oct 20232.4 billion USDIQVIA2023estimate→
Life sciences and patient organization deals1 Jan 2008 to 5 Oct 2023700IQVIA2023estimate→
Median drug approval time2025322 daysCIRS2025actual→
Medicare patient out-of-pocket medicine cost decline2025638 million USDIQVIA2025actual→
Net medicine spending+1 more2025606 billion USDIQVIA2025actual→
Net medicine spending increase202558 billion USDIQVIA2025actual→
New active substance approvals202550CIRS2025actual→
Novel active substance launches+1 more202553IQVIA2025actual→
Novel active substance launches (multi-year total)2021–2025270IQVIA2025actual→
Novel antibiotic approvals20243FDAT12024actual→
Novel drug approvals+2 more202546FDAT12025actual→
Novel drug approvals meeting user fee goal dates202447FDAT12024actual→
Novel drug approvals using expedited programs202433FDAT12024actual→
Novel drugs approved first in domestic market202434FDAT12024actual→
Obesity-approved GIP and GLP-1 agonist medicine spending growth20259.6 billion USDIQVIA2025actual→
Oncology bispecific antibody trial starts+6 more1 Jan 2023 to 27 Sep 2026352ClinicalTrials.govT12026actual→
Patient out-of-pocket medicine cost increase20256 billion USDIQVIA2025actual→
Patient out-of-pocket medicine costs2025110 billion USDIQVIA2025actual→
Pharmaceutical and medicine manufacturing company-funded R&D2023114,225 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing externally funded R&D202311,761 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by domestic companies20232,104 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by foreign companies20239 billion USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D funded by other external sources202379 million USDNCSEST12023actual→
Pharmaceutical and medicine manufacturing R&D intensity202317.8%NCSEST12023actual→
Pharmaceutical and medicine manufacturing total R&D performance+1 more2023125,986 million USDNCSEST12023actual→
  • 2022116,073 million USDNCSEST12022actual→
Prescription medicine use2025210 billion days of therapyIQVIA2025actual→
Prescription medicine use growth20251.5%IQVIA2025actual→
Projected net medicine spending increase2025–2030200 billion USDIQVIA2030forecast→
Radioligand therapy trial starts+6 more1 Jan 2023 to 27 Sep 2026127ClinicalTrials.govT12026actual→
Reference products with biosimilar approvals20248FDAT12024actual→
Share of first-cycle novel drug approvals202474%FDAT12024actual→
Share of novel drug approvals meeting user fee goal dates202494%FDAT12024actual→
Share of novel drug approvals using expedited programs202466%FDAT12024actual→
Share of novel drugs approved first in domestic market202468%FDAT12024actual→

Pharmaceuticals in United States by topic

Primary documents

Sources

83 primary source documents. Every figure on this page traces to one of these.
Document Publisher Authority tier Published Accessed Locator Data points
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies of siRNA, antisense and next-generation oral lipid-lowering drugs in cardiometabolic and transthyretin disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record mentions CRISPR, base or prime editing, zinc-finger nucleases, TALENs or a named gene-editing product with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional drug or biologic studies in ulcerative colitis, Crohn's disease or inflammatory bowel disease not further specified with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States. 1
ClinicalTrials.gov study count: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States Dataset ClinicalTrials.gov T1 Official — 27 Sep 2026 totalCount field of the API response. Query: Interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in the United States. 1
The 2025 EU Industrial R&D Investment Scoreboard Press release European Commission T1 Official 22 Dec 2025 17 Sep 2026 EU: Health and energy sectors shine in a year of slowdown 1
Business R&D Performance in the United States Increases to $722 Billion in 2023 Press release NCSES T1 Official — 17 Sep 2026 Table 2. Funds spent for business R&D performed in the United States, by source of funds, selected industry, and company size: 2023; R&D Performance, by Type of R&D, Industry Sector, and Source of Funding; Sales, R&D Intensity, and Employment of Companies That Performed or Funded R&D 7
Discovery: R&D Activity and Research Publications Press release NCSES T1 Official — 17 Sep 2026 Table DISC-3. Domestic net sales, R&D, and R&D-to-sales ratio for companies that performed or funded U.S. business R&D, by selected industry: 2022 1
CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 Press release FDA T1 Official — 17 Sep 2026 A Record Year for Biosimilar Approvals; CDER’s Effectiveness Bringing New Therapies to Market; Creating a Yearly Snapshot for Approvals 13
Novel Drug Approvals for 2025 Press release FDA T1 Official — 17 Sep 2026 FDA Novel Drug Therapy Approvals for 2025 1
Novel Drug Approvals for 2024 Press release FDA T1 Official — 17 Sep 2026 FDA Novel Drug Therapy Approvals for 2024 1
New Drug Approvals by Six Major Authorities 2016-2025 Press release CIRS T3 Research — 17 Sep 2026 Key Findings 2
U.S. Medicine Use Trends 2026 Press release IQVIA T3 Research — 15 Sep 2026 Other Findings; Key Findings 13
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Press release IQVIA T3 Research — 15 Sep 2026 Global cell and gene therapy spending and share by geography 1
Rethinking Clinical Trial Country Prioritization Press release IQVIA T3 Research — 15 Sep 2026 Country utilization is heavily consolidated in U.S., China and Western European countries 1
Supporting patients through research collaboration Press release IQVIA T3 Research — 16 Sep 2026 Key findings: 2
Global R&D Trends 2026 Press release IQVIA T3 Research — 15 Sep 2026 Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 1
Global R&D Trends 2026 Press release IQVIA T3 Research — 15 Sep 2026 Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 2

Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.

All 116 collected records for United States are published as verified.

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. Each figure's own page carries APA, MLA, Chicago and BibTeX citations naming its original publisher.

StatOrigin. (2026). Pharmaceuticals in United States: statistics. Retrieved from https://statorigin.org/industries/pharmaceuticals/united-states

Get this data as JSON